Clinical meaning
Preventive medicine at the advanced practice level requires understanding the molecular mechanisms underpinning screening and intervention strategies. Statin therapy for primary cardiovascular prevention inhibits HMG-CoA reductase in hepatocytes, upregulating LDL receptor expression and reducing circulating atherogenic lipoprotein particles that drive endothelial injury and plaque formation. GLP-1 receptor agonists used in obesity pharmacotherapy act on pancreatic beta cells to enhance glucose-dependent insulin secretion while simultaneously acting on hypothalamic appetite centers to reduce caloric intake. Varenicline for tobacco cessation is a partial agonist at the alpha-4-beta-2 nicotinic acetylcholine receptor, providing enough dopamine release to reduce cravings while blocking the rewarding effects of nicotine if the patient resumes smoking.